{"id":1352,"date":"2020-07-17T12:21:30","date_gmt":"2020-07-17T10:21:30","guid":{"rendered":"https:\/\/pharmavalue.it\/?p=1352"},"modified":"2021-04-13T12:36:45","modified_gmt":"2021-04-13T10:36:45","slug":"we-live-in-interesting-times-market-access","status":"publish","type":"post","link":"https:\/\/pharmavalue.it\/en\/we-live-in-interesting-times-market-access\/","title":{"rendered":"WE LIVE IN INTERESTING TIMES - MARKET ACCESS"},"content":{"rendered":"<p>The Italian pharmaceutical market environment, from regulatory to regulatory, has always been a highly changeable scenario, both because of continuous technological advances and because of regulations that adapt to innovation and chase urgencies.<br \/>\nWe live in interesting times, we are experiencing an epoch-making moment, the SARS-CoV-2 pandemic; in Italy, all stakeholders are working - some planning, some lobbying with proposals - on a new drug governance. With this infographic, we have tried to imagine the future scenario of market access in these interesting times.<\/p>\n<div class=\"_df_book df-lite\" id=\"df_1354\"  _slug=\"viviamo-in-tempi-interessanti-market-access\" data-title=\"viviamo-in-tempi-interessanti-market-access\" wpoptions=\"true\" thumbtype=\"\" ><\/div><script class=\"df-shortcode-script\" nowprocket type=\"application\/javascript\">window.option_df_1354 = {\"outline\":[],\"backgroundColor\":\"#eeeeee\",\"duration\":\"0\",\"autoEnableOutline\":\"false\",\"autoEnableThumbnail\":\"false\",\"overwritePDFOutline\":\"false\",\"enableDownload\":\"true\",\"direction\":\"1\",\"pageSize\":\"0\",\"soundEnable\":\"false\",\"source\":\"https:\\\/\\\/pharmavalue.it\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/VIVIAMO-IN-TEMPI-INTERESSANTI-MARKET-ACCESS.pdf\",\"wpOptions\":\"true\"}; if(window.DFLIP && window.DFLIP.parseBooks){window.DFLIP.parseBooks();}<\/script>","protected":false},"excerpt":{"rendered":"<p>Il contesto italiano del mercato farmaceutico, da quello normativo a quello regolatorio, \u00e8 sempre stato uno scenario fortemente mutevole, sia per i progressi tecnologici continui, sia per una normativa che si adegua all&#8217;innovazione e rincorre le urgenze. Viviamo in tempi interessanti, stiamo vivendo un momento epocale, la pandemia SARS-CoV-2; in Italia, tutti gli stakeholder stanno [&hellip;]<\/p>\n","protected":false},"author":314,"featured_media":1357,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","footnotes":""},"categories":[38],"tags":[24,35],"class_list":["post-1352","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analisi-di-scenario","tag-covid-19","tag-market-access"],"_links":{"self":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts\/1352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/users\/314"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/comments?post=1352"}],"version-history":[{"count":0,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts\/1352\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/media\/1357"}],"wp:attachment":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/media?parent=1352"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/categories?post=1352"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/tags?post=1352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}